Delcath Systems, Inc. (DCTH)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 872912 · fiscal year ends in Dec
Closing price $14.63 on 29 Oct 2026; 52-week range $8.19 to $17.36.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $95.4M
- Revenue growth
- 35.8%
- Net income, last twelve months
- $532.0K
- Earnings per share
- $0.01
- Gross margin
- 87.1%
- Operating margin
- -1.9%
- Net margin
- 0.6%
- Free cash flow
- $17.5M
- Return on equity
- 0.4%
- Market value
- $506.6M
- Price to earnings
- 1462.5x
- Cash
- $47.5M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 34.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $85.2M | $660.0K | $2.7M | $0.07 | $21.0M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $37.2M | -$12.4M | -$26.4M | -$0.93 | -$19.2M | 10-K filed 6 Mar 2025 |
| FY2023 | 31 Dec 2023 | $2.1M | -$38.2M | -$47.7M | -$2.94 | -$31.3M | 10-K filed 26 Mar 2024 |
| FY2022 | 31 Dec 2022 | $2.7M | -$33.9M | -$36.5M | -$4.12 | -$25.2M | 10-K filed 27 Mar 2023 |
| FY2021 | 31 Dec 2021 | $3.6M | -$24.5M | -$25.6M | -$3.59 | -$22.7M | 10-K filed 27 Mar 2023 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $29.1M | $2.7M | $0.07 |
| Q1 FY2026 | 31 Mar 2026 | $25.0M | -$1.1M | -$0.03 |
| Q4 FY2025 | 31 Dec 2025 | $20.7M | -$1.9M | -$0.05 |
| Q3 FY2025 | 30 Sep 2025 | $20.6M | $830.0K | $0.02 |
| Q2 FY2025 | 30 Jun 2025 | $24.2M | $2.7M | $0.07 |
| Q1 FY2025 | 31 Mar 2025 | $19.8M | $1.1M | $0.03 |
| Q4 FY2024 | 31 Dec 2024 | $15.1M | -$3.4M | -$0.11 |
| Q3 FY2024 | 30 Sep 2024 | $11.2M | $1.9M | $0.06 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| HEPZATO KIT | $78.8M | 92.5% |
| CHEMOSAT | $6.4M | 7.5% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $78.8M | 92.5% |
| Foreign | $6.4M | 7.5% |
Company events
The newest 8-K filings of 410 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 14 Aug 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 14 May 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 3 Mar 2026 | 8-K | Other events | 8.01, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02 |
| 12 Jan 2026 | 8-K | Results, Investor update, Other events | 2.02, 7.01, 8.01, 9.01 |
| 20 Nov 2025 | 8-K | Other events | 8.01 |
| 4 Nov 2025 | 8-K | Results | 2.02 |
| 20 Oct 2025 | 8-K | Results, Investor update, Other events | 2.02, 7.01, 8.01, 9.01 |
| 15 Aug 2025 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 6 Aug 2025 | 8-K | Results | 2.02 |
Every filing
The newest filings with the SEC of 886 held.
| Filed | Form | Period |
|---|---|---|
| 14 Aug 2026 | S-8 | – |
| 14 Aug 2026 | 8-K | 12 Aug 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 14 May 2026 | 8-K | 13 May 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 2 Apr 2026 | ARS | 31 Dec 2025 |
| 2 Apr 2026 | DEFA14A | – |
| 2 Apr 2026 | DEF 14A | 13 May 2026 |
| 3 Mar 2026 | 8-K | 3 Mar 2026 |
| 26 Feb 2026 | 10-K | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 6 Mar 2026 | Pennell Sandra, Chief Financial Officer | Purchase | 5,533 | $9.04 | $50.0K | 77,018 | 6 Mar 2026 |
| 2 Mar 2026 | Michel Gerard J, CHIEF EXECUTIVE OFFICER | Purchase | 11,200 | $8.96 | $100.3K | 342,034 | 3 Mar 2026 |
| 21 Nov 2025 | Sylvester John Richard, Director | Purchase | 4,386 | $8.89 | $39.0K | 14,936 | 25 Nov 2025 |
| 11 Nov 2025 | Michel Gerard J, CHIEF EXECUTIVE OFFICER | Purchase | 11,500 | $8.53 | $98.0K | 330,834 | 13 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock Portfolio Management LLC | 13G | 6.3% | 2.2M |
| 19 Oct 2026 | Rosalind Advisors, Inc. | 13D amended | 9.9% | 6.7M |
| 28 Jul 2026 | BlackRock, Inc. | 13G | 5.3% | 1.8M |
| 27 Apr 2026 | BlackRock, Inc. | 13G amended | 4.98% | 1.7M |
| 20 Mar 2026 | Daniel Kaufman | 13G | 5.08% | 1.8M |
| 10 Feb 2026 | Rosalind Advisors, Inc. | 13D amended | 9.9% | 6.7M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.9M | -3.29% | 6.24 |
| 30 Sep 2026 | 1.9M | -15.78% | 5.37 |
| 15 Sep 2026 | 2.3M | +3.1% | 6.93 |
| 31 Aug 2026 | 2.2M | -4.79% | 4.97 |
| 14 Aug 2026 | 2.4M | -7.01% | 2.28 |
| 31 Jul 2026 | 2.5M | -6.01% | 7.23 |
| 15 Jul 2026 | 2.7M | -6.06% | 7.69 |
| 30 Jun 2026 | 2.9M | -12.99% | 4.85 |
Funds that hold it
From each fund's latest Form 13F.
140 funds held it at 30 Jun 2026: 64 added and 26 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Rosalind Advisors, Inc. | 3,300,389 | $41.6M | 0 |
| BlackRock, Inc. | 2,706,802 | $34.1M | +922,336 |
| Vanguard Capital Management LLC | 1,221,247 | $15.4M | -108,041 |
| Propel Bio Management, LLC | 871,460 | $11.0M | -108,238 |
| Geode Capital Management, LLC | 733,115 | $9.2M | +41,084 |
| State Street Corp. | 679,280 | $8.6M | +14,852 |
| Algert Global LLC | 580,708 | $7.3M | +434,975 |
| Millennium Management LLC | 566,371 | $7.1M | -21,684 |
| Divisadero Street Capital Management, LP | 499,796 | $6.3M | 0 |
| Morgan Stanley | 407,983 | $5.1M | +22,459 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B